In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
Myriad Genetics, Inc (NASDAQ: MYGN) closed the day trading at $11.74 down -14.80% from the previous closing price of $13.78. In other words, the price has decreased by -$14.80 from its previous closing price. On the day, 2.72 million shares were traded.
Ratios:
For a better understanding of MYGN, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.65 and its Current Ratio is at 1.82. In the meantime, Its Debt-to-Equity ratio is 0.20 whereas as Long-Term Debt/Eq ratio is at 0.18.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Craig Hallum on February 12, 2025, initiated with a Buy rating and assigned the stock a target price of $29.
On December 10, 2024, UBS started tracking the stock assigning a Neutral rating and target price of $18.
Leerink Partners Downgraded its Outperform to Market Perform on December 09, 2024, whereas the target price for the stock was revised from $30 to $21.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 11 ’24 when DIAZ PAUL J sold 15,000 shares for $22.93 per share. The transaction valued at 343,950 led to the insider holds 962,378 shares of the business.
DIAZ PAUL J bought 15,000 shares of MYGN for $343,950 on Oct 11 ’24. On Aug 21 ’24, another insider, Ancona Margaret, who serves as the Officer of the company, bought 11,538 shares for $27.82 each.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 1.28 while its Price-to-Book (P/B) ratio in mrq is 1.53.
Stock Price History:
Over the past 52 weeks, MYGN has reached a high of $29.30, while it has fallen to a 52-week low of $12.04. The 50-Day Moving Average of the stock is -12.70%, while the 200-Day Moving Average is calculated to be -44.74%.
Shares Statistics:
A total of 91.30M shares are outstanding, with a floating share count of 87.64M. Insiders hold about 3.73% of the company’s shares, while institutions hold 102.11% stake in the company.
Earnings Estimates
Currently, 9.0 analysts are dedicated to thoroughly evaluating and rating the performance of Myriad Genetics, Inc (MYGN) in the stock market.The consensus estimate for the next quarter is $0.02, with high estimates of $0.09 and low estimates of -$0.03.
Analysts are recommending an EPS of between $0.1 and -$0.1 for the fiscal current year, implying an average EPS of $0.05. EPS for the following year is $0.32, with 14.0 analysts recommending between $0.69 and $0.12.
Revenue Estimates
12 analysts predict $202.23M in revenue for the current quarter. It ranges from a high estimate of $211M to a low estimate of $197M. As of the current estimate, Myriad Genetics, Inc’s year-ago sales were $202.2MFor the next quarter, 12 analysts are estimating revenue of $212.77M. There is a high estimate of $222M for the next quarter, whereas the lowest estimate is $204M.
A total of 13 analysts have provided revenue estimates for MYGN’s current fiscal year. The highest revenue estimate was $879.5M, while the lowest revenue estimate was $840M, resulting in an average revenue estimate of $851.22M. In the same quarter a year ago, actual revenue was $837.6MBased on 14 analysts’ estimates, the company’s revenue will be $941.85M in the next fiscal year. The high estimate is $1.04B and the low estimate is $909.2M.
